ArticleWorld journal of surgical oncology2026
Development and validation of a machine learning model for predicting distant metastasis in patients with renal cell carcinoma: a population-based study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDistant metastasis is the leading cause of death in renal cell carcinoma (RCC), yet accurate prediction tools remain lacking. We aimed to develop and validate a machine learning model to predict synchronous distant metastasis-defined as metastasis present at the time of initial diagnosis-in RCC.
methodsWe identified 106,448 RCC patients from the SEER database (2010-2020), divided into training (n = 52,368), internal validation (n = 22,444), and external validation (n = 31,636) cohorts. Nine machine learning algorithms were compared using area under the curve (AUC), calibration, and decision curve analysis. Model interpretability was assessed using SHAP analysis.
resultsDistant metastasis was present in 10.7% of patients. N1 stage (OR 8.28-9.46), tumor size > 7 cm (OR 6.30-7.72), T4 stage (OR 6.29-8.51), and sarcomatoid histology (OR 1.89-3.28) were independent risk factors, while chromophobe histology (OR 0.04-0.11) and multifocal tumors (OR 0.40-0.53) were protective. Gradient Boosting achieved AUCs of 0.906, 0.906, and 0.926 in training, internal, and external validation cohorts, respectively. The model demonstrated good calibration and clinical utility across threshold probabilities of 5%-80%. Performance remained stable across subgroups and sensitivity analyses. A web calculator was developed ( https://952307952pxw.shinyapps.io/RCC-Calculator/ ).
conclusionsWe developed a machine learning model that accurately predicts synchronous distant metastasis at the time of initial RCC diagnosis, with good generalizability. The online calculator may assist clinicians in risk stratification and individualized decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.